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IntroductIon
The lung is the most common site of metastastic in-
volvement for all invasive neoplasms that develop in 
the human body. Thirty to seventy percent of patients 
who suffer from a malignant neoplasm will develop 
at least one lung metastasis during the course of their 
disease. Metastasectomy is a quite old treatment for 
lung metastases. Tudor Edwards in London (1927) 
performed the resection of a solitary lung metastasis 
from sarcoma of the leg, six years after the initial leg 
amputation. Churchill in Boston (1933) performed a 
formal lobectomy for metastatic to the lung kidney 
carcinoma. Alfred Blalock performed in 1944 a right 
pneumonectomy for a lung metastasis, four years af-
ter resection of a large bowel carcinoma1. Currently, 
surgical treatment is the optional treatment for lung 
metastases from certain tumors which fulfill certain 
strict criteria. 
Pathophysiology-molecular biology
The malignant cells that metastasize to the lung show 
the typical characteristics of uncontrollable and inde-
pendent proliferation, the lack of response to inhibi-
tory signs and resistance to apoptosis and of induction 
of angiogenesis. The tumor cells are released from 
the primary tumor after disruption of the basal lam-
ina and the extracellural matrix, entering the venous 
circulation. Some tumor cells that are released in the 
blood-stream are trapped in the pulmonary capillary 
bed2. A minority will penetrate the pulmonary inter-
stitium and lead to the development of a metastatic 
deposit. There are three main factors that make the 
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lung such a frequent metastatic site. The whole blood 
volume passes through the pulmonary capillary bed 
many times each day, the pulmonary capillary bed is 
the richest in the human body and finally, the high par-
tial pressure of oxygen in the pulmonary interstitium 
significantly contributes to the growth and develop-
ment of the metastasis (“seed” and “soil” theory). The 
tumor cells can also reach the lung through the lym-
phatic system3.
The tumors that tend to more frequently metasta-
size to the lung are choriocarcinoma, Ewing sarcoma, 
malignant melanoma and osteosarcoma. Since they 
are not usual themselves, lung metastases usually de-
velop from the much more frequent colorectal, breast 
and renal cell carcinoma3. We arrange below more 
information for each one of the three most frequent 
primary tumors that give metastases to the lung.
1. Colorectal carcinoma: It is the second most 
frequent malignant disease in the human body and 
is still the second cause of death from cancer among 
humans, despite the progress that has been made in 
the screening of population/early diagnosis and treat-
ment. Although, 2/3 of the patients have potentially 
completely resected primary tumor, 30%-50% will 
develop distant metastases 2 to 3 years after colec-
tomy4. Lung metastases from colon cancer usually ap-
pear to follow liver metastatic disease. In other, less 
frequent instances, lung metastases are diagnosed at 
the same time with the diagnosis of the primary tu-
mor or develop later in the absence of liver metastases 
(skip metastases). The main prognostic factors after 
metastasectomy are: 
1. Long disease free interval (DFI)
2. Carcinoembryonic antigen (CEA) < 5ng/ml before 
thoracotomy 
3. Single isolated metastasis with diameter less than 
3 cm
4. Absence of mediastinal lymphadenotpathy. 
Around 10% of the patients will have concur-
rent liver and lung metastases. The survival rate will 
drop to almost half in this case (40 months versus 87 
months if liver metastases don’t exist)5.The prognosis 
is better if the metastases are resected from both or-
gans and aggressive treatment is also recommended in 
metachronous liver and pulmonary metastases6,7.
2. Breast carcinoma: Three percent of all women 
with breast cancer will develop a solitary pulmonary 
lesion that will be detected with plain chest radiogra-
phy during the course of their disease. Thirty to forty 
percent of them are found to be metastases from the 
primary tumor. On the other, hand lung metastases are 
the cause of death in 25% of women with breast can-
cer8. The role of surgical treatment of lung metastases 
from breast cancer isn’t absolutely clear because of its 
combination with chemotherapy and hormonal ther-
apy9. Lastly, there are some indications that surgical 
resection of the primary tumor leads to a phenotype 
change of the lung metastases with increased prolif-
eration without resistance to apoptosis10.
3. Renal cell carcinoma: Lungs are the most com-
mon site for metastases from renal cell carcinomas. 
Surgical resection appears to have positive outcome 
even though immunotherapy is another choice. The 
main prognostic factors are the number of metastases, 
the existence of mediastinal lymphadenopathy, the 
long DFI and the ability for complete resection which 
brings the 5-year survival rate to 45% against 8% in 
case of incomplete resection9.
General Aspects of Lung Metastasectomy
The common criteria which are used in order to select 
patients that would benefit from surgical treatment of 
their metastases are the following: 
Control of the primary tumor or the possibility to 
be controlled. 
Long DFI that is the length of time it takes for a 
cancer to recur once it has been considered eradicated. 
Longer DFIs are associated with better prognosis.
Complete resection of the metastatic tumor with 
preservation of adequate healthy lung parenchyma. 
Complete resection is associated with 38% 5-year sur-
vival, while incomplete resection drops the survival 
rate to 10%. The number of metastases and their pre-
cise location are also considered. For over 4 metas-
tases the 5 year survival is 20% while for less than 3 
is 40%11. For unilateral or less than 3 metastases and 
FEV1>80% surgical treatment is indicated. For bilat-
eral or more that 3 metastases the decision is taken 
after careful consideration of all these factors. 
Extrathoracic metastatic disease must be exclud-
ed12.
Lack of alternative therapy with similar or better 
results than surgery.
Absolute contraindications are considered to be 
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mediastinal lymph node invasion, FEV1 or DLCO 
< 40% of the predicted and age more than 80 years. 
Relative contraindications for metastasectomy are 
BMI > 35 kg/m2 or BMI < 15 kg/m2. Multiple bilat-
eral metastases and previous lung or liver metastasec-
tomy (in colorectal carcinomas) are not considered 
to be contraindications13. However, it is believed that 
the number of metastases is an absolutely negative 
prognostic factor because it is highly associated with 
the malignancy of the primary tumor and the metas-
tasectomy will not change the course of aggressive 
cancers14. The preoperative detection of high levels of 
tumor markers is a negative prognostic factor, while 
men seem to have better prognosis15.
While in primary lung cancer anatomical resec-
tion is preferred, pulmonary metastases tend to be 
peripherally located and limited resection as wedge 
resection or simple enucleation of the tumor deposit 
with clear margins is usually adequate treatment9. 
When metastatic disease is more centrally located 
within the lung parenchyma, the anatomic resection 
(ie, segmentectomy, lobectomy, bilobectomy or even 
pneumonectomy) may be performed with any effort 
made to preserve as much pulmonary parenchyma as 
possible in each case12. Pneumonectomy is required 
in case of a large metastasis or a metastasis critically 
involving pulmonary hilar structures. Resection with 
clear margins (R0) is associated with longer survival 
rates16. Extended resections (en bloc resection of lung 
parenchyma and chest wall, diaphragm, superior vena 
cava, pericardium) are accepted and can be followed 
by reconstruction of the resected structures17. Accord-
ing to the International Registry of Lung Metastases 
the mortality rate following extended resections is 
completely accepted (1.2% following lobectomy-bi-
lobectomy and 3.2% following pneumonectomy)1.
Repeated metastasectomies result in higher sur-
vival rate18. Repeated metastasectomies are mainly 
performed for metastases from colorectal cancer and 
sarcomas. In theory, up to 4 metastasectomies are ac-
cepted, while longer DFIs are related with 48% five-
year survival rate9.
Concerning mediastinal lymph node invasion, tho-
racic surgeons don’t seem to agree if lymphadenopa-
thy will affect their decision to perform metastasecto-
my in a patient. In colorectal cancer with synchronous 
liver metastases and in central lung metastasis it is 
more possible for the mediastinal lymph nodes to be 
affected19. Thoracic surgeons believe that hilar and 
mediastinal nodes should always be resected or at 
least sampled in order to have a more accurate prog-
nosis. The resection lasts only 15 to 30 minutes and 
there is no significant raise in mortality rate13. A dif-
ferent approach is that lymph nodes should always be 
removed during all major lung parenchyma resections 
and during minor resections for pulmonary metastases 
from colorectal and renal cell cancer18.
Surgical treatment
Patients who suffer from extra-thoracic metastatic dis-
ease are not candidates for surgical resection of their 
pulmonary metastases and the first choice treatment 
includes systemic therapies, despite the fact that these 
are neither curing the patients nor prolonging surviv-
al. Preoperative or postoperative systemic therapy has 
no significant impact on long-term survival rate, con-
sistent with data published elsewhere11. It is widely 
accepted that surgical resection (metastasectomy) im-
proves long-term survival of patients who comply the 
criteria for being selected for such a therapeutic ap-
proach, and thus it is considered as a significant option 
for pulmonary metastases. Moreover, the improved 
survival that follows resection of lung metastases has 
broadened current surgical indications and the num-
ber of patients who are chosen to be treated surgically 
increases continuously. Different approaches (formal 
thoracotomy or video-assisted thoracic surgery) and 
different surgical strategies are used in daily practice 
to perform metastasectomy.
Surgical approach
1) Formal thoracotomy provides the best choice for 
pulmonary metastasectomy. It allows palpation of the 
whole lung and consequently the detection of addi-
tional small metastatic deposits that are not visible on 
chest CT scan. Thoracotomy offers the best chance 
to achieve resection of larger nodules with clear mar-
gins.
2) Video-Assisted Thoracic Surgery (VATS) is the 
less invasive surgical approach in comparison to for-
mal thoracotomy. It is widely used and it offers the 
benefit of low postoperative pain, faster postoperative 
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recovery, decreased length of hospital stay and earlier 
return to everyday activity. VATS resection is better 
suited for solitary, larger than 1cm but less than 3cm 
metastatic peripheral pulmonary nodules. The major 
reported disadvantage of VATS metastasectomy is the 
inability to palpate the lung and to detect other, pos-
sible metastatic, lesions during the operation20. 
Surgical strategies and modern instrumentation
1) Wedge resection of metastatic nodules using sta-
pling devices is the most common used method to re-
sect metastatic nodules. It provides a fast and airtight 
resection that is mainly suitable for peripherally lo-
cated in lung parenchyma nodules. The common dis-
advantage of wedge resection is the amount of healthy 
lung parenchyma surrounding the malignant nodule 
that is sacrificed during this type of resection using 
either stapling devices or hand-sewing techniques. 
2) Enucleation of the metastatic nodules is ap-
plied for the resection of multiple metastatic lesions 
or deeply situated lesions. The main advantage of enu-
cleation is the elimination of healthy lung parenchyma 
to be sacrificed (lung parenchyma sparing technique) 
that can be crucial in patients with limited pulmonary 
reserve. Enucleation is also helpful when facing deep-
seated lesions or nodules that are located in the broad 
surface of the lungs. When this technique is chosen, 
the lung should be inflated. The fact that the lung 
needs to be in an inflated state makes enucleation an 
unsuitable technique to be performed with VATS21.
Instruments for enucleation
Enucleation can be performed with different instru-
ments the simplest of which is cautery (electrosurgi-
cal device). Cautery has the disadvantage of damage 
of the adjacent to the nodule pulmonary parenchyma, 
while hemostasis and aerostasis are limited making 
necessary the application of multiple additional su-
tures. In contrary, the use of the new generation lasers 
(1318-nm wavelength Nd:YAG laser, 40 watt) for the 
enucleation of pulmonary metastases has three ma-
jor advantages. First of all, it allows sparing as much 
lung tissue as possible, when resecting lesions that are 
deep-seated. Secondly, it causes the minimal defor-
mity and damage of the adjacent lung tissue. Finally, 
when the lesion is next to a major bronchus or vessel, 
it is possible to dissect the maximum margin of tissue 
around the lesion, without causing any injury to the 
adjacent major structures. The surface of the lung is 
simply over-sewed by a continuous suture for reap-
proximation of the visceral pleura in order to mini-
mize postoperative air-leak21.
The LigaSure system is an electrothermal bipolar 
tissue sealing technique specifically used for non-ana-
tomic, staplerless pulmonary resection. The emission 
of bipolar energy leads to vessel compression, which 
makes it easier to check the bleeding and allows lo-
cal hemostasis. The experience in using this system 
in thoracic surgery is still limited. Surgical parameters 
(amount of postoperative bleeding, operating and hos-
pitalization times) seem similar to the ones observed 
when resection is performed with stapler devices, but 
LigaSure system allows the minimal thermal dam-
age21.
Ultracision scalpel (Harmonic scalpel) works by 
liberating energy (in the form of an ultrasonic wave) 
at the tip of the scalpel. The main advantage of Har-
monic scalpel is the reduced lateral spreading of the 
heat which results in the ability to operate near vulner-
able structures and the minimal smoke production21. 
The saline-enhanced thermal sealing helps to convert 
the electrical energy into thermal into the tissue. The 
continuous flow of saline is cooling the tissue and the 
peak limit temperatures are limited to 100oC or less. 
This differs from the conventional electrosurgical de-
vices in which tissue temperature even exceeds 300°C. 
The results of the high tissue temperatures are tissue 
desiccation, char formation, smoke generation, elec-
trodes sticking to tissue, and undesired lateral thermal 
damage. The saline-enhanced thermal sealing avoids 
these undesirable tissue effects, while being able to 
achieve sufficient hemostasis and pneumostasis of the 
lung tissue. This specific technique is used to perform 
nodulectomies and wedge resections. The coagulated 
vessel and bronchiole need to be individually divided 
and thus the operation time is more than the one need-
ed in the conventional electrocautery or laser proce-
dures. During the operation the lung is deflated and it 
is common that more than the desired functional lung 
tissue is finally removed. The saline-enhanced ther-
mal sealing is used in both thoracoscopic and open 
procedures21. 
We have to emphasize that all these devices (Liga-
Sure system, Ultracision scalpel and saline-enhanced 
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thermal sealing) are not the best choice when han-
dling with lung parenchyma resection, because of 
their probable inability to achieve permanent aerosta-
sis. The need for additional deep sutures to achieve 
aerostasis omits their theoretical advantages to spare 
lung parenchyma. Late appearance of air leaks that 
prolongs chest tube drainage is another problem that 
is associated with their use in enucleation of pulmo-
nary metastases. Laser resection and cautery still re-
main the standard instrumentation for the enucleation 
of pulmonary metastatic nodules.
Case-series of lung metastasectomies
We arrange below a retrospective review of 25 pa-
tients who underwent surgical resection of their lung 
metastases from different primary tumors. They were 
all admitted and treated in AHEPA Hospital of Thes-
saloniki between 2007 and 2011. 
Demographic data (name, age), characteristics 
of the metastases (number, site, size), DFI, the type 
of surgical approach, levels of CEA before surgery 
(among patients with colorectal cancer) were record-
ed. The above mentioned characteristics of the 25 pa-
tients who underwent pulmonary metastasectomy are 
presented in Table 1.
Most of the patients were referred to the Thoracic 
Surgery Depertment from the Oncology Department 
after detection of a possible malignant pulmonary le-
sion. All patients underwent a chest HRCT in order 
to evaluate respectability and the size and precise lo-
cation of the nodules. Their respiratory function was 
evaluated with spirometry.
Different types of resections were performed de-
pending on the location of the lesion, the extent of 
invasion and the preoperative respiratory function, 
while four of them underwent repeated metastasec-
tomies. All the 25 patients who underwent metasta-
sectomy were evaluated in the department of clinical 
oncology and systemic treatment was administered by 
the clinical oncologists. The main results of metasta-
sectomy appear also in Table 1.
The median DFI was quite long (24 months) while 
the survival rate is quite good extending up to 44 
months Wedge resection or enucleation of pulmonary 
metastases or combination of wedge resection and 
enucleation of multiple lesions was performed in 16 
out of the 25 patents (64%) (Table 1) Gross involve-
ment of the major fissure or involvement of the lung 
hilum made necessary pneumonectomy for eradica-
tion of the disease in two patients. Gross involvement 
of the minor fissure required bilobectomy (1 patient) 
for eradication of the tumor, while deeply situated or 
larger tumors (> 5cm) required lobectomy (6 patients). 
(Table 1).
Multiple surveys consider the level of CEA as 
a negative prognostic factor for patients with me-
tastases from colorectal cancer. We were able 
to record the level before metastasectomy in 5 
patients. Two of them had low levels of CEA 
(< 5ng/ml) and a single lung lesion, while the rest three 
had elevated CEA serum levels. One patient with el-
evated serum CEA levels before metastasectomy had 
two lung metastases, while another one underwent 3 
metastasectomies due to recurrent lung metastases. 
Apart from that, the level of CEA obtained from three 
patients with history of colorectal carcinoma that are 
not included in the present case-series could be as-
sociated with the aggressiveness of the primary tumor 
(colorectal cancer). Two patients who had a single 
lung lesion had very low levels of CEA (< 5ng/ml). 
Their lesions proved to represent benign nodules after 
resection, while a third patient had very high serum 
CEA levels (111ng/ml) and suffered from simulta-
neous metastatic disease to the thoracic spine. From 
the thoracic surgeons’ point of view, it would seem 
reasonable to always obtain a CEA serum level dur-
ing the preoperative evaluation of the patient, and if it 
is high it seems realistic to proceed with whole body 
PET-CT scan22.
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table 1. Demographic data, main characteristics and results of the 25 patients who underwent pulmonary metastasectomy.
Age in years (mean, range) 65.2  (3-84)
Gender Male: 13, Female: 12
Primary tumor site
Colorectal: 12
Breast: 3
Kidney: 3
Skin: 2
Uterus: 1
Head-Neck: 1
Liver: 1
Bladder: 1
Soft Tissue sarcoma: 1
Disease free interval in months
(median and range) 24 (2-120)
Number of resected metastases
(mean and range) 1.9 (1-9)
Location of metastases
right Lung
Upper Lobe: 3
Middle Lobe: 3
Lower Lobe: 5
Major fissure (involvement of 3 lobes)
Minor fissure (involvement of 2 lobes)
Left Lung
Upper Lobe: 9
Lower Lobe: 6
Hilum: 1
Endobronchial: 1
Maximum diameter of the resected 
metastases in cm (mean ± SD, range) 2.33 ± 1.5 (0.5 – 7.0) 
Type of resection
Wedge resection, enucleation or combination: 16
Lobectomy: 6
Bilobectomy: 1
Pneumonectomy: 2
Repeated metastasectomy 4 patients (1-3 metastasectomies)
Surgical approach Formal thoracotomy: 23VATS resection: 2
Preoperative CEA levels (ng/ml) in 5 
patients with metastasis from colorectal 
cancer (median and range)
10.14 (1.07 – 275.5)
Follow-up after treatment in 15 out of 
the 25 patients
11 survivors (3-37) – median: 20.5
4 deaths (9-44) – median: 12.0
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ΠΕΡΙΛΗΨΗ: Η χειρουργική θεραπεία είναι η αποτελεσματικότερη θεραπεία για τις πνευμονικές μεταστάσεις από συγκε-
κριμένους εξωθωρακικούς όγκους, όταν πληρούνται ορισμένα κριτήρια, όπως είναι ο απόλυτος έλεγχος της πρωτοπαθούς 
εστίας, το μεγάλο διάστημα ελεύθερο νόσου και η απουσία άλλων εξωθωρακικών μεταστάσεων (με εξαίρεση τις ηπατικές 
μεταστάσεις από καρκίνωμα του παχέος εντέρου και του ορθού, που μπορούν να υποβληθούν σε ριζική εκτομή). Παράταση 
της επιβίωσης με τη μεταστασεκτομή ή ακόμη και με επαναλαμβανόμενες μεταστασεκτομές) αναμένεται σε ασθενείς που 
παρουσιάζουν μικρό αριθμό πνευμονικών μεταστάσεων (<3), όταν οι μεταστατικές εστίες μπορούν να αντιμετωπιστούν 
ριζικά με τη χειρουργική και όταν οι λεμφαδένες του μεσοθωρακίου δεν είναι προσβεβλημένοι από τη νόσο. Περιορισμένη 
εκτομή του πνευμονικού παρεγχύματος, με τη μορφή της σφηνοειδούς εκτομής, της εκπυρήνυσης και της τυπικής τμηματε-
κτομής, αποτελεί την ιδανική χειρουργική θεραπεία για τις πνευμονικές μεταστάσεις. Μεγαλύτερες εκτομές, όπως λοβεκτο-
μή, διλοβεκτομή ή ακόμη και πνευμονεκτομή μπορεί να απαιτηθούν σε μεγαλύτερες, βαθιά εντοπιζόμενες στο πνευμονικό 
παρέγχυμα μεταστάσεις. Η τυπική θωρακοτομή είναι η καλύτερη προσπέλαση, ενώ η θωρακοσκοπική αφαίρεση ενδείκνυται 
σε μονήρεις, επιφανειακές μεταστάσεις. Η εκπυρήνυση των πνευμονικών μεταστάσεων γίνεται με την εφαρμογή ηλεκτρο-
διαθερμίας ή των νέας γενιάς Nd;YAG lasers, με στόχο τη διάσωση κατά την επέμβαση όσο το δυνατό περισσότερου υγιούς 
πνευμονικού παρεγχύματος. 
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